Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | GLI1 | P08151 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15386556 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP2D6BCHECASP3GLI1 | |
| SCHEMBL8260203 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP2D6BCHECASP3GLI1 | |
| SCHEMBL14434721 | 0.94 | CYP3A4 (0.37) | CYP3A4CYP2D6BCHECASP3GLI1 | |
| SCHEMBL8261848 | 0.94 | CYP3A4 (0.37) | CYP3A4CYP2D6BCHECASP3GLI1 | |
| SCHEMBL20095980 | 0.87 | BCHE (0.36) | CYP3A4CYP2D6BCHECASP3GLI1 | |
| SCHEMBL20095979 | 0.87 | BCHE (0.36) | CYP3A4CYP2D6BCHECASP3GLI1 | |
| SCHEMBL5597367 | 0.84 | CYP3A4 (0.40) | CYP3A4CYP2D6BCHEL3MBTL3ACE | |
| SCHEMBL20063354 | 0.81 | CYP3A4 (0.38) | CYP3A4CYP2D6DPP4ACE | |
| SCHEMBL25663879 | 0.81 | CYP3A4 (0.38) | CYP3A4CYP2D6DPP4ACE | |
| SCHEMBL20063360 | 0.81 | CYP3A4 (0.38) | CYP3A4CYP2D6BCHEL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | claimed |
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | claimed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | claimed |
| EP-1786792-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-05-23 | — | — | EP | claimed |
| WO-2006011631-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-02-02 | — | — | WO | claimed |
| EP-0449191-B1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | BANYU PHARMA CO LTD (JP) | 1996-07-03 | — | — | EP | claimed |
| US-5438054-A | Antibacterial agent | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-01 | — | — | US | claimed |
| WO-1991014687-A1 | 2-(SUBSTITUTED PYRROLIDINYLTHIO)CARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-03 | — | — | WO | claimed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3416957-B1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDIN-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| WO-2006011631-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-02-02 | — | — | WO | disclosed |
| EP-0449191-B1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | BANYU PHARMA CO LTD (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5438054-A | Antibacterial agent | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-01 | — | — | US | disclosed |
| US-5374720-A | A thienamycins bactericides has nontoxic, side effect reduction against the kidney and central nervous system | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-12-20 | — | — | US | disclosed |
| EP-0449191-A1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | UPF1, HNRNPUL1, HNRNPUL2 | CYP3A4 4881/4885CYP2D6 4878/4885BCHE 4736/4885 |
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | TLR7, TLR9, TLR1 | CYP3A4 2582/4885CYP2D6 2903/4885BCHE 4620/4885 |
| US-20070010531-A1 | Substituted pyrazole compounds | HTR3A, HTR1A, HTR1D | CYP3A4 251/4885CYP2D6 195/4885BCHE 3839/4885 |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | CYP3A4 4080/4885CYP2D6 4386/4885BCHE 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.